Navigation Links
Gentler chemotherapy before stem cell transplant causes long-term remission of follicular lymphoma

ATLANTA - Treating relapsed follicular lymphoma patients with a milder chemotherapy regimen before they receive a blood stem cell transplant from a donor resulted in long-term complete remission for 45 of 47 patients in a clinical trial, researchers at The University of Texas M. D. Anderson Cancer Center report at the 49th annual meeting of the American Society of Hematology.

The two patients who had relapsed after the treatment regained a complete response after additional therapy.

"Our results show that this approach may actually be curative of follicular lymphoma," says lead author Issa Khouri, M.D., professor in M. D. Anderson's Department of Stem Cell Transplantation. "No other treatments produce this type of response."

The traditional treatment before receiving a matched stem cell donation consists of higher-dose chemotherapy that kills the lymphoma cells and shuts down the patient's own blood-producing stem cells - a process called myeloablation. While waiting for the donor's stem cells to engraft in the bone marrow and to begin producing blood, patients are vulnerable to infection, bleeding, and anemia.

Early research by Khouri and colleagues indicated that using a nonmyeloablative chemotherapy approach could control the lymphoma while sparing patients the side effects of high-dose chemotherapy. The transplanted blood stem cells launch an immune system attack on the lymphoma, a process called graft-vs.-lymphoma immunity.

"Our early results were encouraging. But with follicular lymphoma you need a long follow-up to see if the results hold," Khouri says. "This disease tends to recur later on, sometimes years after chemotherapy."

All patients in the present trial have been followed for at least five years, some for up to nine years. Trial patients had received 2 to 7 different chemotherapy regimens. Eight had received transplants of their own stem cells. At transplantation, 29 were in partial remission and 18 were in complete remission.

All 47 achieved complete remission after receiving matched blood stem cells from donors. One patient relapsed at 18 months. After receiving a donor lymphocyte infusion, the patient began a continuous complete response at 24 months. The other patient relapsed at 20 months and was found to have graft failure. Since treatment with rituximab, this patient has been in complete remission for four years.

Seven patients died during the trial, none from follicular lymphoma, Khouri notes. The 40 remaining patients all remain in remission. Overall survival at six years is 85 percent and current progression-free survival is 83 percent.

Acute graft-vs.-host disease (GVHD) arose in 11 percent of patients. Another 51 percent had chronic graft-vs.-host disease. GVHD was treated with immunosuppressive therapy. Khouri notes that only five patients in the study group remain on immunosuppressive therapy.

Long-term follow-up also allowed researchers to thoroughly gauge side effects, or toxicity, of the non-myeloablative approach. "It reduces toxicity significantly," Khouri says. "Even elderly patients can have this done."

Patients received fludarabine, cyclophosphamide and rituximab for three days before transplantation. Tacrolimus and methotrexate were used to prevent graft-vs.-host disease.

Follicular lymphoma is a Non-Hodgkin lymphoma, with about 12,000 new cases diagnosed annually.


Contact: Scott Merville
University of Texas M. D. Anderson Cancer Center

Related medicine news :

1. Chemotherapy may be culprit for fatigue in breast cancer survivors
2. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
3. To evade chemotherapy, some cancer cells mimic stem cells
4. New chemotherapy regimen prolongs survival in difficult-to-treat childhood brainstem gliomas
5. PET scans can accurately detect a breast tumors response to chemotherapy
6. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
7. Medicare modernization act did not change chemotherapy as feared
8. HER-2 status predicts success of chemotherapy in breast cancer treatment, study finds
9. Cancer conflict with chemotherapy treatment
10. Intra-arterial combination chemotherapy induces long-term survival for hepatocellular carcinoma
11. Jefferson researchers show chemotherapy and radiation together extend lung cancer patients lives
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... Scientists in Seattle and Vancouver compared the ... with or without mesothelioma. Surviving Mesothelioma has just posted an article on the new ... Laboratories in Seattle and the University of British Columbia found that certain genetic alterations ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... establishment of telemedicine programs in communities throughout Georgia, along with affiliate organizations, Alabama ... schedule for their regional telehealth summits for Fall 2015. , Each of ...
(Date:10/13/2015)... ... 13, 2015 , ... California Southern University has named Dr. ... her Doctor of Nursing Practice from the renowned Johns Hopkins University—comes to CalSouthern ... Dr. McLeod’s long and successful nursing practice included a variety of patient care, ...
(Date:10/13/2015)... ... October 13, 2015 , ... Local Gold’s Gym franchise owner, ... Conference on August 26. Berry, who owns and operates Gold's Gym Cheyenne ... growing Gold’s Gyms in the United States. A brand leader in global fitness, Gold’s ...
(Date:10/13/2015)... ... October 13, 2015 , ... Breathing is ... do not breathe correctly. According to T’ai Chi (also spelled “Taiji”) and Qigong ... breathe correctly, in concert with the 7,000 year old tradition they teach, can ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... , Oct. 13, 2015 WuXi PharmaTech ... and technology platform company serving the pharmaceutical, biotechnology, ... has launched a mobile version of OncoWuXi, the ... to access oncology models and data on the ... and at any time to identify relevant tumor ...
(Date:10/13/2015)... 13, 2015 Health Gorilla ( ) today ... – a secure platform for clinical data and communications ... about and manage healthcare in the US. The launch follows ... a combined total of $4.4M raised to date, with ... True Ventures , Harris Barton , Orfin Ventures ...
(Date:10/13/2015)... DUBLIN , Oct. 8, 2015 Research ... of the "World Anti-counterfeit Pharmaceuticals and Cosmetics Packaging ... report to their offering. --> ... packaging market to grow at a CAGR of 15.7% ... The hologram authentication technology segment accounted for about ...
Breaking Medicine Technology: